Trial Profile
CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CLBH589DUS108T
- 18 Feb 2021 Status changed from active, no longer recruiting to discontinued.
- 11 Aug 2020 Planned primary completion date changed from 16 May 2021 to 1 Mar 2021.
- 11 Aug 2020 Status changed from recruiting to active, no longer recruiting.